Cat. No.: HY-N0596

Panaxadiol

(Synonyms: 20(R)-Panaxadiol)

4 Cited Publications

Avis client

Based on 4 publication(s) in Google Scholar

Panaxadiol (20(R)-Panaxadiol) is an orally active HIF-1α/STAT3 inhibitor. Panaxadiol can suppress HIF-1α and STAT3 then lead to downregulation of programmed cell death-ligand 1 (PD-L1) expression. Panaxadiol shows anticancer, cardioprotective, anti-arrhythmic, and antioxidative activities.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.89%
CAS No.: 19666-76-3
Formule: C₃₀H₅₂O₃
Masse moléculaire:460.73

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Panaxadiol Chemical Structure

CAS No.: 19666-76-3

Size

Prix

Stock

Quantité

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Obtenir un devis Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Obtenir un devis Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (4)
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Bioz

Activité biologique

Description

Voir tous les produits spécifiques à Isoform HIF/HIF Prolyl-Hydroxylase :

Voir tous les produits spécifiques à Isoform STAT :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	43.13 μM Compound: PD	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 21439693]
A549	IC₅₀	44.57 μM Compound: PD	Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 30568759]
HeLa	IC₅₀	>100 μM Compound: PD	Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 30568759]
Hep 3B2	IC₅₀	31.7 μM Compound: PD	Cytotoxicity against human Hep3B cells assessed as reduction in cell viability incubated for 24 hrs under normaxic condition by MTT assay Cytotoxicity against human Hep3B cells assessed as reduction in cell viability incubated for 24 hrs under normaxic condition by MTT assay	[PMID: 33130293]
HepG2	IC₅₀	37.91 μM Compound: PD	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 21439693]
MCF7	IC₅₀	52.62 μM Compound: PD	Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 30568759]
U2OS	IC₅₀	26.81 μM Compound: PD	Cytotoxicity against human U2OS cells after 48 hrs by MTT assay Cytotoxicity against human U2OS cells after 48 hrs by MTT assay	[PMID: 21439693]
U-87MG ATCC	IC₅₀	>100 μM Compound: PD	Cytotoxicity against human U87 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against human U87 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 30568759]

In Vitro

Panaxadiol (1-10 μM, 12 h) inhibits PD-L1 expression in human colon cancer cells^[1].
Panaxadiol (1-10 μM, 12 h) inhibits the expression of PD-L1 by suppressing HIF-1α and STAT3 in HCT116 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

HCT116, SW620 and HT-29 colon cancer cells
Concentration:

1, 3, and 10 μM
Incubation Time:

12 hours
Result:

Decreased the expression of PD-L1 protein and mRNA in a dose-dependent manner.

Western Blot Analysis^[1]

Cell Line:

HCT116 cells
Concentration:

1, 3, and 10 μM
Incubation Time:

12 hours
Result:

Inhibited hypoxia-induced nuclear accumulation of HIF-1α in a dose-dependent manner.
Inhibited STAT3 phosphorylation at Tyr705 in a dose-dependent manner under both normoxic and hypoxic conditions.

In Vivo

Panaxadiol (oral gavage; 10 or 30 mg/kg; once every 3 days; 30 d) inhibits the growth of HCT116 cells in a xenograft model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

BALB/c athymic nude mice injected with HCT116 cells^[1]
Dosage:

10 or 30 mg/kg
Administration:

Oral gavage; 10 or 30 mg/kg; once every 3 days; 30 days
Result:

Inhibited the protein levels of HIF-1α, p-STAT-3 (Tyr705), PD-L1 and VEGF in tumour tissues in a dose-dependent manner.

Chemical Information

CAS No. 19666-76-3
Appearance Solid
Masse moléculaire 460.73
Formule C₃₀H₅₂O₃
Color White to off-white
SMILES

C[C@@]1(CC[C@@H]2O)[C@](C[C@H]3O)([H])[C@](CC[C@@]1([H])C2(C)C)(C)[C@@]4(C)[C@@]3([H])[C@]([C@](CCC5)(C)OC5(C)C)([H])CC4
Synonyms

20(R)-Panaxadiol
Structure Classification
- Terpenoids
- Triterpenes
Initial Source
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (4)

All

Sort by:

Journal Impact Factor

Acta Pharmacol Sin

Ginsenoside (20)S-APPT induces ferroptosis in hepatocellular carcinoma and cholangiocarcinoma by targeting FSP1. [Abstract]

2025 Jun 23. PMID: 40550962
Drug Dev Res

Panaxadiol Attenuates Brain Damage by Inhibiting Ferroptosis in a Rat Model of Cerebral Hemorrhage. [Abstract]

2025 Apr;86(2):e70079. PMID: 40117294
Exp Cell Res

CMTM4 promotes PD-L1-mediated macrophage apoptosis by enhancing STAT2 phosphorylation in sepsis. [Abstract]

2025 Mar 21:114519. PMID: 40122504
Gene

Panaxadiol inhibits the proliferation and immune evasion of esophageal squamous cell carcinoma cells by suppressing HIF-1α/STAT3/PD-L1 pathway. [Abstract]

2025 Oct 23:149829. PMID: 41138756

Solvant et solubilité

In Vitro:

DMSO : 100 mg/mL (217.05 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Ethanol : 20 mg/mL (43.41 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.1705 mL

10.8523 mL

21.7047 mL

5 mM

0.4341 mL

2.1705 mL

4.3409 mL

10 mM

0.2170 mL

1.0852 mL

2.1705 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (5.43 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.43 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (281 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Wang Z, et al. Panaxadiol inhibits programmed cell death-ligand 1 expression and tumour proliferation via hypoxia-inducible factor (HIF)-1α and STAT3 in human colon cancer cells. Pharmacol Res. 2020;155:104727. [Content Brief]

[2]. Myong Hak Ri, et al. Development of natural products for anti-PD-1/PD-L1 immunotherapy against cancer. J Ethnopharmacol. 2021 Dec 5;281:114370. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
Ethanol / DMSO	1 mM	2.1705 mL	10.8523 mL	21.7047 mL	54.2617 mL
	5 mM	0.4341 mL	2.1705 mL	4.3409 mL	10.8523 mL
	10 mM	0.2170 mL	1.0852 mL	2.1705 mL	5.4262 mL
	15 mM	0.1447 mL	0.7235 mL	1.4470 mL	3.6174 mL
	20 mM	0.1085 mL	0.5426 mL	1.0852 mL	2.7131 mL
	25 mM	0.0868 mL	0.4341 mL	0.8682 mL	2.1705 mL
	30 mM	0.0723 mL	0.3617 mL	0.7235 mL	1.8087 mL
	40 mM	0.0543 mL	0.2713 mL	0.5426 mL	1.3565 mL
DMSO	50 mM	0.0434 mL	0.2170 mL	0.4341 mL	1.0852 mL
	60 mM	0.0362 mL	0.1809 mL	0.3617 mL	0.9044 mL
	80 mM	0.0271 mL	0.1357 mL	0.2713 mL	0.6783 mL
	100 mM	0.0217 mL	0.1085 mL	0.2170 mL	0.5426 mL

Keywords

Panaxadiol

4 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Panaxadiol

Epigenetics Compound Library

Immunology/Inflammation Compound Library

JAK/STAT Compound Library

Kinase Inhibitor Library

Metabolism/Protease Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Small Molecule Immuno-Oncology Compound Library

Anti-Aging Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Lipid Compound Library

Oxygen Sensing Compound Library

Medicine Food Homology Compound Library

Terpenoids Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Protein-protein Interaction Inhibitor Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Anti-Prostate Cancer Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Miao Ethnicity Medicine Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Cell Proliferation Compound Library

Lactic Acid Metabolic Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Posttranslational Modification Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Panaxadiol

Voir tous les produits spécifiques à Isoform HIF/HIF Prolyl-Hydroxylase

Voir tous les produits spécifiques à Isoform STAT

Activité biologique

Chemical Information

Publications (4)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Panaxadiol Related Classifications

Cat. No.: HY-N0596